One-hit effects and cancer

Cancer Prevention Research

Volumn 3, Issue 1, 2010, Pages 12-15

  Iniesta, Maria D ^a   Chien, Janet ^a   Wicha, Max ^a   Merajver, Sofia D ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

BREAST CANCER; CANCER DIAGNOSIS; DIAGNOSTIC ACCURACY; GENE FREQUENCY; GENETIC ANALYSIS; GERM LINE; HETEROZYGOTE; HUMAN; MICROSCOPY; MOLECULAR BIOLOGY; MUTATION; ONCOGENE; PRIORITY JOURNAL; SHORT SURVEY; BREAST TUMOR; FEMALE; GENETIC PREDISPOSITION; GENETICS; NOTE; OVARY TUMOR; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; OVARIAN NEOPLASMS;

EID: 77649203720     PISSN: 19406207     EISSN: None     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-09-0249     Document Type: Short Survey

References (28)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. Burke W, Daly M, Garber J, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 1997;277:997-1003.
3. Wooster R, Weber BL. Breast and ovarian cancer. N Engl J Med 2003;348:2339-47.
4. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71.
5. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378:789-92.
6. Wooster R, Neuhausen SL, Mangion J, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994;265:2088-90.
7. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007;25:1329-33.
8. Knudson AG, Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 1971;68:820-3.
9. Bellacosa A, Godwin AK, Peri S, et al. Altered gene expression in morphologically normal epithelial cells from heterozygous carriers of BRCA1 or BRCA2 mutations. Cancer Prev Res 2010;3:48-61.
10. Watson MA, Dintzis S, Darrow CM, et al. Mammaglobin expression in primary, metastatic, and occult breast cancer. Cancer Res 1999;59:3028-31.
11. Bernstein JL, Godbold JH, Raptis G, et al. Identification of mammaglobin as a novel serum marker for breast cancer. Clin Cancer Res 2005;11:6528-35.
12. Sjodin A, Ljuslinder I, Henriksson R, Hedman H. Mammaglobin and lipophilin B expression in breast tumors and their lack of effect on breast cancer cell proliferation. Anticancer Res 2008;28:1493-8.
13. Liu S, Ginestier C, Charafe-Jauffret E, et al. BRCA1 regulates human mammary stem/progenitor cell fate. Proc Natl Acad Sci U S A 2008;105:1680-5.
14. Lim E, Vaillant F, Wu D, et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 2009;15:907-13.
15. Charafe-Jauffret E, Ginestier C, Iovino F, et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 2009;69: 1302-13.
16. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004;4:814-9.
17. Kopelovich L. Phenotypic markers in human skin fibroblasts as possible diagnostic indices of hereditary adenomatosis of the colon and rectum. Cancer 1977;40:2534-41.
18. Danes BS. Increased in vitro tetraploidy: tissue specific within the heritable colorectal cancer syndromes with polyposis coli. Cancer 1978;41:2330-4.
19. Kopelovich L. Heritable colorectal cancer and cancer genes: systemic expressions. Mol Carcinog 1993;8:3-6.
20. Yeung AT, Patel BB, Li XM, et al. One-hit effects in cancer: altered proteome of morphologically normal colon crypts in familial adenomatous polyposis. Cancer Res 2008;68:7579-86.
21. Stoyanova R, Clapper ML, Bellacosa A, et al. Altered gene expression in phenotypically normal renal cells from carriers of tumor suppressor gene mutations. Cancer Biol Ther 2004;3:1313-21.
22. Ioannidis JP. Microarrays and molecular research: noise discovery? Lancet 2005;365:454-5.
23. Michiels S, Koscielny S, Hill C. Interpretation of microarray data in cancer. Br J Cancer 2007;96:1155-8.
24. Pawitan Y, Michiels S, Koscielny S, Gusnanto A, Ploner A. False discovery rate, sensitivity and sample size for microarray studies. Bio-informatics 2005;21:3017-24.
25. Domchek SM, Weber BL. Clinical management of BRCA1 and BRCA2 mutation carriers. Oncogene 2006;25:5825-31.
26. Finch A, Beiner M, Lubinski J, et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA 2006;296:185-92.
27. King MC, Wieand S, Hale K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 2001;286:2251-6.
28. McLaughlin JR, Risch HA, Lubinski J, et al. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol 2007;8:26-34.